Amgen buys Horizon-Bloomberg
2022.12.12 03:17
Amgen buys Horizon-Bloomberg
Budrigannews.com – (NASDAQ) Amgen Inc. is going to purchase Horizon Therapeutics, a biotech company (NASDAQ:) Bloomberg News reported on Monday that Plc would make its largest acquisition, valued at approximately $26 billion.
According to the report, which cites a person who is familiar with the situation, the American biotechnology company has offered approximately $116.5 for each Horizon share. In comparison to Horizon’s closing price of $97.29 on Friday, the offer is approximately 20% higher.
The report comes after Sanofi, a French pharmaceutical company (NASDAQ:) declared on Sunday that it will no longer offer Horizon for sale.
More Australian ASX 200 in red zone
Horizon Therapeutics, which has a market capitalization of approximately $22 billion, announced last month that it was in talks with Johnson & Johnson, Sanofi, and Amgen Inc. ‘s Janssen Global Services unit, with all three participating actively in this year’s deal-making.
Last week, Janssen also pulled out of the race, stating that it would not be making an offer for Horizon.
Sunday was the first day that the Wall Street Journal reported that Amgen is in advanced talks to buy Horizon.
